Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Próximos ensayos clínicos
-
Seoul National University HospitalSamil Pharmaceutical Co., Ltd.ReclutamientoSarcopenia | Artroplastia total de rodillaCorea del Sur
-
Stanford UniversityAún no reclutandoLeucemia mieloide aguda | Síndromes mielodisplásicos | Neoplasia mieloproliferativaEstados Unidos
-
Cheng QiReclutamientoPost-hepatectomy HypoalbuminemiaPorcelana
-
Stanford UniversityAún no reclutandoInsuficiencia hepáticaEstados Unidos
-
Istanbul Aydın UniversityAún no reclutandoDolor de cuello | Síndrome de dolor miofascial | Trastornos musculoesqueléticos relacionados con el trabajoTurquía (Türkiye)
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.Aún no reclutandoCarcinoma endometrial recidivante | Carcinoma endometrial avanzado | Carcinoma endometrial metastásico | Cáncer de endometrio en estadio III | Cáncer de endometrio en estadio IVEstados Unidos
-
University of Colorado, DenverReclutamientoEscoliosis idiopática del adolescente (AIS) | Escoliosis neuromuscularEstados Unidos
-
University of FloridaAmerican Heart AssociationReclutamientoInsuficiencia cardíaca con fracción de eyección conservada (HFPEF)Estados Unidos
-
UNC Lineberger Comprehensive Cancer CenterAún no reclutandoLeucemia | Leucemia linfoblástica aguda | Linfoma linfoblástico | Leucemia aguda | Leucemia linfoide agudaEstados Unidos
-
Korea University Anam HospitalThe Catholic University of Korea; Keimyung University Dongsan Medical Center; Medical...Aún no reclutandoCáncer urológico | Lesión miocárdica tras cirugía no cardiaca | Principales eventos cardiovasculares adversos (MACE)
-
Montefiore Medical CenterAún no reclutandoCesarean Scar Defect (Isthmocele)Estados Unidos
-
SanofiAún no reclutandoVacunación contra el VRSChequia
Clinical Research Jobs
-
Philippines - Manila
-
Taiwan - Taipei
-
United States - Shrewsbury
-
Germany - Munich
-
Germany - Nordrhein-Westfalen - CologneAustria
-
Serbia - Belgrade
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China